![Paul Meers](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Paul Meers
Nessuna posizione attualmente
Profilo
Paul Meers is a Principal Scientist at Transave, Inc. He received a PhD in Biochemistry from Cornell University.
He was an Assistant Professor at Boston University.
Precedenti posizioni note di Paul Meers
Società | Posizione | Fine |
---|---|---|
Transave, Inc.
![]() Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Direttore Tecnico/Scientifico/R&S | 30/08/2012 |
Formazione di Paul Meers
Cornell University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Società collegate
Aziende private | 1 |
---|---|
Transave, Inc.
![]() Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Health Technology |
- Borsa valori
- Insiders
- Paul Meers